Daily Endocrinology Research Analysis
Analyzed 183 papers and selected 3 impactful papers.
Summary
Analyzed 183 papers and selected 3 impactful articles.
Selected Articles
1. Bempedoic acid directly binds and activates PPARα.
Using transcriptomics, biochemistry, and X-ray crystallography, this study shows that bempedoic acid directly binds the PPARα ligand-binding domain, stabilizes its active conformation, and induces fatty acid oxidation in hepatocytes and mouse liver. Activation of PPARα targets occurred independently of ACSVL1 conversion to bempedoyl-CoA, and fatty acid oxidation required PPARα, establishing direct PPARα activation as a core mechanism of action.
Impact: This mechanistic discovery clarifies the molecular basis of bempedoic acid’s lipid-lowering effects and positions it as a direct PPARα activator with potential applications beyond LDL reduction.
Clinical Implications: Understanding BA as a direct PPARα activator informs combination strategies (e.g., with statins or fibrates), potential benefits in MASLD/NAFLD, and safety considerations when co-targeting nuclear receptors.
Key Findings
- Bempedoic acid directly binds the PPARα ligand-binding domain and stabilizes its active conformation (X-ray crystallography).
- BA robustly induces PPARα signaling and fatty acid oxidation in primary hepatocytes and mouse liver.
- Activation of PPARα targets occurs independently of ACSVL1-mediated conversion to bempedoyl-CoA; PPARα is required for BA-induced fatty acid oxidation.
Methodological Strengths
- Multi-platform approach integrating transcriptomics, biochemistry, and structural biology.
- In vivo validation in mouse liver supports translational relevance.
Limitations
- Preclinical work without direct human clinical outcome confirmation.
- Dose-response and long-term systemic effects were not fully explored in humans.
Future Directions: Assess BA–PPARα activation in human tissues, evaluate synergy or redundancy with fibrates, and explore indications in MASLD and atherogenic dyslipidemia.
Bempedoic acid (BA) is a recently approved drug that lowers cholesterol and hepatic lipids, yet its mechanism of action remains incompletely understood. Here, we combine transcriptomic, biochemical, and structural approaches to show that BA directly binds to and activates peroxisome proliferator-activated receptor alpha (PPARα). BA treatment robustly induced PPARα signaling and fatty acid oxidation in primary hepatocytes and mouse liver. Through X-ray crystallography, we uncovered that BA binds to the ligand-binding domain of PPARα and stabilizes its active conformation. BA activated PPARα target genes independently of very-long-chain acyl-coenzyme A (CoA) synthetase (ACSVL1), the liver-enriched enzyme that converts BA to its bempedoyl-CoA form. Notably, BA-mediated induction of fatty acid oxidation required PPARα. Together, this work reveals direct PPARα activation as a key mechanism of BA action, providing a molecular basis for its lipid-lowering effects and suggesting broader therapeutic potential beyond the liver.
2. Data-driven classification of metabolic-associated steatotic liver disease subtypes predicting hepatic and extrahepatic progression.
Using a multi-task deep LASSO feature selection followed by clustering, the authors identified four MASLD subtypes with distinct hepatic and extrahepatic risks. External validation in health-check and NHANES cohorts showed that clusters with low muscle mass/inflammation or severe insulin resistance/visceral adiposity had higher all-cause and cardiovascular mortality.
Impact: Provides an implementable, validated phenotyping framework to stratify MASLD beyond steatosis severity, integrating cardio-renal-hepatic risks for precision management.
Clinical Implications: Supports targeted surveillance and therapy selection (e.g., sarcopenia/inflammation focus for Cluster 3; aggressive metabolic therapy for Cluster 4), and enriches risk-based referral pathways.
Key Findings
- Four MASLD clusters with distinct phenotypes and risks were identified in a biopsy-anchored discovery cohort.
- External validation in 6,172 health-check participants and 7,406 NHANES III participants confirmed prognostic relevance; Clusters 3 and 4 had higher all-cause and CVD mortality.
- Cluster 4 (severe insulin resistance and visceral adiposity) showed the highest PNPLA3 risk allele frequency and high cardio-liver-kidney complication risk.
Methodological Strengths
- Novel multi-task deep LASSO feature selection with clustering anchored to biopsy data.
- Robust external validation across two large cohorts with long-term follow-up.
Limitations
- Observational design limits causal inference; potential residual confounding.
- Algorithm generalizability and implementation pathways in diverse healthcare settings need prospective testing.
Future Directions: Prospective deployment to guide risk-based interventions, integration with imaging and omics, and testing treatment responsiveness across clusters.
BACKGROUND: Metabolic-associated steatotic liver disease (MASLD) is a heterogeneous condition with highly variable outcomes. We aimed to distinguish the subtypes of MASLD that were associated with varying risks of hepatic and extrahepatic outcomes. METHODS: An innovative multi-task deep least absolute shrinkage and selection operator (LASSO) algorithm was developed for feature selection in the discovery cohort (n = 1111, 87.6% [973/1111] of biopsy-proved MASLD), followed by clustering analysis in MASLD. Validation was performed in 6172 individuals who undertook health check-ups (MASLD: 43.9% [2710/6172], mean follow-up 27.6 months) and 7406 participants from the Third National Health and Nutrition Examination Survey (NHANES III) (MASLD: 37.3%, mean follow-up 280.2 months). RESULTS: Four clusters with distinct risks of hepatic and extrahepatic outcomes were identified in the discovery cohort: Cluster 1 characterized by subcutaneous adiposity, modest metabolic disorders, but lower risk of cardiovascular disease (CVD); Cluster 2 characterized by significant hyperlipidemia, substantial liver damage, and increased hepatic fibrosis risk; Cluster 3 characterized by low muscle mass, remarkable chronic systemic inflammation, and a higher risk of cardiovascular-kidney complications; and Cluster 4 characterized by severe insulin resistance, visceral adiposity, poor glucose and lipid control, and severe liver damage, conferring a high risk of cardiovascular-liver-kidney complications. Additionally, Cluster 4 exhibited the highest frequencies of PNPLA3 risk alleles. The prognostic relevance was further confirmed in external validation cohorts. Specifically, Clusters 3 and 4 had increased risks of all-cause and CVD-related mortality. CONCLUSIONS: We developed a novel algorithm that identified four MASLD clusters, each characterized by distinct clinical features and varying risks of hepatic and extrahepatic outcomes. This classification facilitates the precise integration of MASLD risk stratification and management within the cardiovascular-liver-kidney-metabolic framework.
3. The Effects of Marine Fatty Acid Omega-3 Supplements on Incident Fractures and Bone Mineral Density in Generally Healthy Adults.
In 25,871 generally healthy adults followed 5.3 years, marine omega-3 supplementation (1 g/day) did not reduce incident total, nonvertebral, or hip fractures. A subcohort showed a small increase in whole-body aBMD without improvements at spine/hip or peripheral vBMD/strength indices.
Impact: A large, high-quality RCT delivers definitive negative evidence, discouraging routine omega-3 use for fracture prevention in community-dwelling adults.
Clinical Implications: Clinicians should not recommend marine omega-3 supplements solely for fracture prevention; focus should remain on proven strategies (exercise, calcium/vitamin D adequacy, antiresorptives/anabolics as indicated).
Key Findings
- No reduction in total, nonvertebral, or hip fractures with 1 g/day marine omega-3 over a median 5.3 years in 25,871 adults.
- Small increase in whole-body aBMD, but no effect at spine/hip aBMD or peripheral vBMD/strength indices in a 771-participant subcohort.
- No serious adverse events observed with omega-3 supplementation.
Methodological Strengths
- Large randomized, placebo-controlled, 2x2 factorial design with adjudicated fracture outcomes.
- Comprehensive densitometric and pQCT assessment in a predefined subcohort.
Limitations
- Participants were not selected for low bone density or high fracture risk, potentially diluting effects.
- The BMD subcohort size limits detection of small site-specific changes; dose and baseline omega-3 status not optimized for bone outcomes.
Future Directions: Targeted trials in high-risk skeletal populations and stratification by baseline omega-3 status may clarify niche benefits; mechanistic studies on bone remodeling endpoints could refine hypotheses.
Although preclinical studies suggest that omega-3 fatty acids may benefit skeletal health, there are few randomized controlled trials investigating effects of supplemental omega-3 on bone outcomes. This VITamin D and OmegA-3 TriaL (VITAL) ancillary study investigated effects of marine omega-3 (1 g/d; EPA + DHA in a 1.2:1 ratio) vs. placebo supplements on fracture risk and bone density/structure. VITAL is a 2x2 factorial randomized placebo-controlled trial that studied effects of supplemental marine omega-3 fatty acids and/or vitamin D3 vs. placebo on cancer and cardiovascular events. The intervention took place from November 2011 through December 2017; median follow-up was 5.3 yr. The study included 25 871 U.S. men (aged ≥50) and women (aged ≥55) without baseline cancer or cardiovascular disease, not selected for low bone density or fracture history. Primary outcomes were adjudicated incident total, nonvertebral, and hip fractures in the overall cohort. In a subcohort of 771 individuals, we measured 2-yr changes in areal bone mineral density (aBMD) by dual X-ray absorptiometry, and volumetric bone mineral density (vBMD), cortical thickness, and bone strength indices at the radius and tibia by peripheral quantitative computed tomography. Supplemental omega-3 vs. placebo had no effect on total (HR, 1.02; 95% CI, 0.92-1.13; p = .73), nonvertebral (HR, 1.01; 95% CI, 0.91-1.12; p = .80), or hip fractures (HR, 0.89; 95% CI, 0.61-1.30; p = .55). In the subcohort, omega-3 supplementation resulted in a small increase in whole body aBMD (+0.03% vs. -0.41%, p = .006) and no effect on aBMD at the spine or hip, or vBMD or bone strength indices at the radius or tibia. No serious adverse effects were observed. Supplementation with marine omega-3 fatty acids did not reduce incident fracture risk. It led to a small increase in whole body aBMD but had no other effects on BMD or bone strength measures compared to placebo in generally healthy midlife and older adults. Animal studies suggest that omega-3 fatty acid supplements may help bone health. However, there are few human clinical trials assessing the impact of supplemental omega-3 on bone density and fracture risk. This ancillary study to the VITamin D and OmegA-3 TriaL (VITAL) investigated if supplementation with marine omega-3 fatty acids improves bone outcomes in 25 871 men and women (average age 67.1 yr). Supplemental omega-3 fatty acids, compared to placebo, did not reduce total, non-spine, or hip fractures over 5.3 yr of treatment. Omega-3 fatty acid supplementation for 2 yr also did not improve spine or hip bone density in a smaller group of 771 participants. In this very large study, marine omega-3 fatty acid supplementation did not reduce incident fracture risk or benefit bone density in community-dwelling midlife to older adults.